Zhonghua Yi Xue Za Zhi. 2023 Feb 7;103(5):319-328. doi: 10.3760/cma.j.cn112137-20220708-01508.
Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms (MPN), with the highest incidence. Thromboembolism is the most common complication of PV, which has significant effects on the quality of life and survival of patients. To standardize the diagnosis, treatment and prevention strategies of thromboembolism associated with PV, the Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPN) Association affiliated to Chinese Medicine Education Association has reached the following consensus based on available proofs from evidence-based medicine after repeated considerations. The consensus covers risk stratification, diagnosis and treatment of PV, multidisciplinary management of PV thromboembolism, and patient follow-up, thereby providing the reference for the standardized diagnosis, treatment and management of thromboembolism for Chinese PV patients.
真性红细胞增多症(PV)是骨髓增殖性肿瘤(MPN)的一种亚型,发病率最高。血栓栓塞是PV最常见的并发症,对患者的生活质量和生存有重大影响。为规范PV相关血栓栓塞的诊断、治疗和预防策略,中国中医药教育协会附属的骨髓增生异常综合征/骨髓增殖性肿瘤(MDS/MPN)协会在反复考量后,基于循证医学的现有证据达成以下共识。该共识涵盖PV的风险分层、诊断和治疗、PV血栓栓塞的多学科管理以及患者随访,从而为中国PV患者血栓栓塞的规范化诊断、治疗和管理提供参考。